Teva Pharmaceutical Indus Analyst Ratings
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
CyberArk Software Analyst Ratings
Guggenheim Reiterates Buy on CyberArk Software, Maintains $300 Price Target
CyberArk Software Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on CyberArk Software, Maintains $300 Price Target
JMP Securities Reiterates Market Outperform on CyberArk Software, Maintains $310 Price Target
CyberArk Software Analyst Ratings
Morgan Stanley Maintains Overweight on NICE, Lowers Price Target to $240
Northland Capital Markets Maintains Outperform on NICE, Maintains $305 Price Target
Citigroup Maintains Buy on NICE, Raises Price Target to $346
Wedbush Reiterates Outperform on NICE, Maintains $250 Price Target
NICE Analyst Ratings
Rosenblatt Maintains Buy on NICE, Lowers Price Target to $225
RBC Capital Cuts Price Target on NICE to $230 From $265, Maintains Outperform Rating
Wix.com Analyst Ratings
B of A Securities Maintains Buy on Wix.com, Raises Price Target to $183
Teva Pharmaceutical Indus Analyst Ratings
CyberArk Software Analyst Ratings
Canaccord Genuity Maintains Buy on CyberArk Software, Lowers Price Target to $280